Sanofi (EPA:SAN) Given a €89.50 Price Target by UBS Group Analysts
Sanofi (EPA:SAN) has been assigned a €89.50 ($104.07) target price by stock analysts at UBS Group in a research report issued to clients and investors on Friday, Borsen Zeitung reports. The firm currently has a “buy” rating on the stock. UBS Group’s target price would suggest a potential upside of 6.42% from the company’s current price.
Several other equities research analysts also recently weighed in on the stock. Bank of America set a €100.00 ($116.28) price target on shares of Sanofi and gave the company a “buy” rating in a research report on Friday, September 13th. Kepler Capital Markets set a €88.00 ($102.33) price target on shares of Sanofi and gave the company a “buy” rating in a research report on Thursday, October 31st. Jefferies Financial Group set a €95.00 ($110.47) price target on shares of Sanofi and gave the company a “buy” rating in a research report on Thursday, October 31st. Goldman Sachs Group set a €81.00 ($94.19) target price on shares of Sanofi and gave the stock a “neutral” rating in a research report on Monday, November 4th. Finally, HSBC set a €79.00 ($91.86) target price on shares of Sanofi and gave the stock a “neutral” rating in a research report on Friday, August 2nd. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Sanofi has an average rating of “Buy” and a consensus price target of €89.12 ($103.62).
Shares of SAN opened at €84.10 ($97.79) on Friday. The firm’s 50 day moving average price is €82.70. Sanofi has a twelve month low of €63.09 ($73.36) and a twelve month high of €92.97 ($108.10).
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Featured Story: Outstanding Shares
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.